CompoAtlas

Cheveux Peau et Ongles

Food supplement declared in France, declaration No 2021-4-1458, decision dated 26 April 2021

Cheveux Peau et Ongles is a food supplement declared in France. Status: déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité). 1 rule of use applies to its ingredients (limits and warnings).

Brand
not provided
Food business operator placing the product on the market
ORONALYS SARL
Status
Déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité)
Form
Gélule
Daily dose
2 gélules par jour
Intended populations
Homme, Femme
Not recommended for (according to the manufacturer)
Femmes allaitantes, Antécédent de cancer du sein, Enfants (moins de 12 ans), Femmes enceintes
Objectives stated by the manufacturer (these are not authorised claims)
Peau, Cheveux et ongles

Declaration 175217, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.

Regulatory points

Declared composition

Plants

PlantPartPreparationPer day
Bambusa bambos (L.) VossExsudatExtrait sec hydroalcoolique140 mg
Arctium lappa L.RacineExtrait sec aqueux140 mg
Medicago sativa L.Parties aériennesExtrait sec aqueux120 mg

Other active ingredients

NamePer day
Méthylsulfonate de méthanenot declared
Nacrenot declared

Additives

E414, Hydroxypropyl Méthyl Cellulose

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Photograph the packaging

Label warnings

Ce complément alimentaire doit être utilisé dans le cadre d’un régime alimentaire varié et équilibré. Il est important d’avoir un mode de vie sain. Ne pas dépasser la dose journalière recommandée. Conserver dans un endroit frais et sec. Ne convient pas aux enfants, aux femmes ayant des antécédents personnels ou familiaux de cancer du sein, enceintes et en période d’allaitement. Tenir hors de portée des enfants.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Arctium lappa L.
    Read the warning, when it applies and the studies cited

    Burdock - Arctium Lappa - Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Brinker 2010; Barnes et al. 2007).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Do not use if you are pregnant (Brinker 2010).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Condition of application: All products.

    Stop use if hypersensitivity/allergy occurs (Brinker 2010).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: All products except those making a diuretic claim.

    When using this product diuretic effect may occur.

    Health Canada monograph dated 19 December 2025

    BURDOCK - ARCTIUM LAPPA - Topical

    Cautions and warnings

    For external use only.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Brinker 2010; Barnes 2007).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product avoid contact with eyes and mucous membranes. If contact occurs, rinse thoroughly with water.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Keep out of reach of children. If swallowed, call a poison control centre or get medical help right away.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (Brinker 2010).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 28 February 2025

  • Medicago sativa L.
    Read the warning, when it applies and the studies cited

    ALFALFA - MEDICAGO SATIVA

    Route of administration: Oral

    Cautions and warnings

    Applies to products providing more than 900 mg of Alfalfa dried herb top/leaf, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners, birth control medication or hormone therapy (Brinker 2010; Barnes et al. 2007; Boon and Smith 2004).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Condition of application: All products.

    Do not use if you are pregnant or breastfeeding (Brinker 2010; Barnes et al. 2007; Boon and Smith 2004).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Applies to products providing more than 900 mg of Alfalfa dried herb top/leaf, per day.

    Do not use if you have a history of systemic lupus erythematosus (Brinker 2010; Barnes et al. 2007; Boon and Smith 2004).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 29 November 2024

  • Méthylsulfonate de méthane
    Read the warning, when it applies and the studies cited

    MSM

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Known adverse reactions

    When using this product you may experience gastrointestinal discomfort/disturbances (Kim et al. 2005).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 19 December 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Other declarations with the same name

In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

List recorded in 2021. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line